ACTUATE THERAPEUTICS
Actuate Therapeutics provides advanced research for the treatment of high-impact cancers and neurodegenerative diseases. It is a private biopharmaceutical company focused on the development of compounds for use in the treatment of cancer and inflammatory diseases leading to fibrosis and neurodegeneration. The company aims to discover, develop, and commercialize new agents that target GSK-3ฮฒ. Actuate Therapeutics is currently advancing its lead molecule, 9-ING-41, toward the clinic in 2017. Ong... oing research has demonstrated significant anti-tumor activity in many in vivo models of difficult-to-treat cancers, including cancers of the brain, pancreas, lung, and breast. We are unaware of any published research demonstrating the kind of efficacy in treatment-resistant glioblastoma that we have been able to achieve with 9-ING-41. Importantly, the toxicity and pharmacokinetic profiles of the drug candidate are quite attractive.
ACTUATE THERAPEUTICS
Social Links:
Industry:
Biotechnology Medical Pharmaceutical
Founded:
2015-01-01
Address:
Fort Worth, Texas, United States
Country:
United States
Website Url:
http://www.actuatetherapeutics.com
Total Employee:
11+
Status:
Active
Contact:
(847) 986-4190
Email Addresses:
[email protected]
Total Funding:
65.02 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Analytics Google Maps Content Delivery Network Global Site Tag
Similar Organizations
Cabaletta Bio
Cabaletta Bio has adapted clinically-validated and FDA-approved CAR T cell technology to target B cell-mediated autoimmune diseases.
ExpressCells
ExpressCells creates custom cell lines for biological research and drug discovery.
Iroko Pharmaceuticals
Iroko Pharmaceuticals is a global specialty pharmaceutical company dedicated to advancing the science of analgesia.
LucasPye BIO
A Contract Development and Manufacturing Organization (CDMO) that manufactures protein-therapeutic and viral-therapeutic drug products.
PhaseBio Pharmaceuticals
PhaseBio is a clinical-stage biopharmaceutical company that develops drugs for cardiovascular diseases, endocrine, and metabolic disorders.
Slingshot Biosciences
Slingshot Biosciences develops next-generation synthetic cells for diagnostics and therapeutics.
Trevarx Biomedical
Trevarx Biomedical is a biomedical startup that develops new radiopharmaceuticals.
Vivodyne
Vivodyne develops an automated robotic system that discovers life-changing drugs and cellular therapies.
Current Advisors List
Current Employees Featured
Founder
Investors List
DEFTA Partners
DEFTA Partners investment in Series B - Actuate Therapeutics
Kairos Ventures
Kairos Ventures investment in Series B - Actuate Therapeutics
Bios Partners
Bios Partners investment in Series B - Actuate Therapeutics
Kairos Ventures
Kairos Ventures investment in Series B - Actuate Therapeutics
DEFTA Partners
DEFTA Partners investment in Series B - Actuate Therapeutics
Tech Coast Angels
Tech Coast Angels investment in Series B - Actuate Therapeutics
Bios Partners
Bios Partners investment in Series B - Actuate Therapeutics
Tech Coast Angels
Tech Coast Angels investment in Convertible Note - Actuate Therapeutics
Official Site Inspections
http://www.actuatetherapeutics.com Semrush global rank: 6.08 M Semrush visits lastest month: 1.13 K
- Host name: actuate.tempurl.host
- IP address: 207.246.122.8
- Location: Piscataway United States
- Latitude: 40.5511
- Longitude: -74.4606
- Metro Code: 501
- Timezone: America/New_York
- Postal: 08854
More informations about "Actuate Therapeutics"
Actuate Therapeutics - Crunchbase Company Profile
Actuate Therapeutics provides advanced research for the treatment of high-impact cancers and neurodegenerative diseases. It is a private biopharmaceutical company focused on the development of compounds for use in the treatment โฆSee details»
Improving Clinical Outcomes in Cancer Treatment - Actuate โฆ
Our focus on glycogen synthase kinase-3ฮฒ (the enzyme GSK-3ฮฒ) has led to the development of the therapeutic candidate elraglusib (formerly known as 9-ING-41).Elraglusib has shown โฆSee details»
Actuate Therapeutics, Inc. | LinkedIn
Actuate Therapeutics, Inc. | 239 followers on LinkedIn. Actuate Therapeutics, Inc. is a pharmaceuticals company based out of 1401 FOCH ST, Fort Worth, Texas, United States.See details»
Investor Relations | Actuate Therapeutics
4 days ago Actuate is a clinical-stage biopharmaceutical company dedicated to developing [cutting-edge] therapies for cancers with high unmet needs. The companyโs product candidate, elraglusib is a small molecule GSK-3 inhibitor โฆSee details»
Actuate Therapeutics, Inc. (ACTU) Company Profile
Aug 13, 2024 Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The companyโs lead product candidate is Elraglusib Injection, a novel glycogen โฆSee details»
Actuate Therapeutics - Overview, News & Similar companies
Actuate Therapeutics contact info: Phone number: (817) 887-8455 Website: www.actuatetherapeutics.com What does Actuate Therapeutics do? Actuate is a clinical stage โฆSee details»
Actuate Therapeutics Announces Pricing of Initial Public Offering
Aug 13, 2024 CHICAGO and FORT WORTH, Texas, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Nasdaq: ACTU) (the โCompanyโ), a clinical stage โฆSee details»
Actuate Therapeutics Receives FDA Orphan Drug Designation for ...
Aug 1, 2023 CHICAGO and FORT WORTH, Texas, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, today โฆSee details»
Actuate Therapeutics Receives FDA Orphan Drug Designation
Aug 1, 2023 CHICAGO and FORT WORTH, Texas, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, today โฆSee details»
Actuate Therapeutics Announces Initiation of a Multicenter โฆ
Feb 7, 2022 CHICAGO and FORT WORTH, Texas, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, today โฆSee details»
UPDATE -- Actuate Therapeutics Announces Poster - GlobeNewswire
Apr 10, 2023 CHICAGO and FORT WORTH, Texas, April 10, 2023 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, announced โฆSee details»
Actuate Therapeutics Announces Poster Presentations at the 2023 โฆ
May 30, 2023 CHICAGO and FORT WORTH, Texas, May 30, 2023 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, announced โฆSee details»
News and Media | Actuate Therapeutics Investors
Nov 12, 2024 Cookie Duration Description; cookielawinfo-checkbox-analytics: 11 months: This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent โฆSee details»
Actuate Therapeutics Announces Poster Presentations at the
May 30, 2023 CHICAGO and FORT WORTH, Texas, May 30, 2023 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, announced โฆSee details»
Actuate Therapeutics Announces First Patient Enrolled in Phase 2 ...
Mar 1, 2022 Elraglusib combination Phase 2 trial with retifanlimab based on observed synergy with immune checkpoint inhibitors, and preclinical and early clinical data supporting โฆSee details»
TIMELINE | Actuate Therapeutics, Inc.
Cookie Duration Description; cookielawinfo-checkbox-analytics: 11 months: This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in โฆSee details»
Actuate Therapeutics Announces First Patient Enrolled in
Mar 1, 2022 CHICAGO and FORT WORTH, Texas, March 01, 2022 (GLOBE NEWSWIRE) -- Actuate Therapeutics and The University of Kansas Cancer Center today announced the โฆSee details»
Our Pipeline of Cancer Therapies | Actuate Therapeutics
Cookie Duration Description; cookielawinfo-checkbox-analytics: 11 months: This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in โฆSee details»
Media and Resources | Actuate Therapeutics
Sep 18, 2024 2024-AACR- FOLFIRINOX with glycogen synthase kinase-3 beta (GSK-3ฮฒ) inhibitor elraglusib and transforming growth factor-ฮฒ (TGFฮฒ) inhibitor losartan in untreated โฆSee details»